Cargando…

Antithrombotics in heart failure

Heart failure is a common clinical condition associated with high morbidity and mortality rate despite significant improvements in pharmacotherapy and implementation of medical procedures. Patients with heart failure are at an increased risk of developing arterial and venous thrombosis, which contri...

Descripción completa

Detalles Bibliográficos
Autores principales: Miličić, Davor, Samardžić, Jure, Petričević, Mate
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Croatian Medical Schools 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295078/
https://www.ncbi.nlm.nih.gov/pubmed/25559833
http://dx.doi.org/10.3325/cmj.2014.55.621
_version_ 1782352788365246464
author Miličić, Davor
Samardžić, Jure
Petričević, Mate
author_facet Miličić, Davor
Samardžić, Jure
Petričević, Mate
author_sort Miličić, Davor
collection PubMed
description Heart failure is a common clinical condition associated with high morbidity and mortality rate despite significant improvements in pharmacotherapy and implementation of medical procedures. Patients with heart failure are at an increased risk of developing arterial and venous thrombosis, which contribute to the high rate of adverse events and fatal outcomes. Many heart failure patients routinely receive antithrombotic therapy due to the presence of a specific indication for its use, like ischemic heart disease or atrial fibrillation. However, there is no solid evidence to support the routine use of antithrombotic agents in all heart failure patients. This article reviews the evidence for using antithrombotic therapy in heart failure patients.
format Online
Article
Text
id pubmed-4295078
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Croatian Medical Schools
record_format MEDLINE/PubMed
spelling pubmed-42950782015-01-21 Antithrombotics in heart failure Miličić, Davor Samardžić, Jure Petričević, Mate Croat Med J Advanced Heart Failure Heart failure is a common clinical condition associated with high morbidity and mortality rate despite significant improvements in pharmacotherapy and implementation of medical procedures. Patients with heart failure are at an increased risk of developing arterial and venous thrombosis, which contribute to the high rate of adverse events and fatal outcomes. Many heart failure patients routinely receive antithrombotic therapy due to the presence of a specific indication for its use, like ischemic heart disease or atrial fibrillation. However, there is no solid evidence to support the routine use of antithrombotic agents in all heart failure patients. This article reviews the evidence for using antithrombotic therapy in heart failure patients. Croatian Medical Schools 2014-12 /pmc/articles/PMC4295078/ /pubmed/25559833 http://dx.doi.org/10.3325/cmj.2014.55.621 Text en Copyright © 2014 by the Croatian Medical Journal. All rights reserved. http://creativecommons.org/licenses/by/2.5/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Advanced Heart Failure
Miličić, Davor
Samardžić, Jure
Petričević, Mate
Antithrombotics in heart failure
title Antithrombotics in heart failure
title_full Antithrombotics in heart failure
title_fullStr Antithrombotics in heart failure
title_full_unstemmed Antithrombotics in heart failure
title_short Antithrombotics in heart failure
title_sort antithrombotics in heart failure
topic Advanced Heart Failure
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295078/
https://www.ncbi.nlm.nih.gov/pubmed/25559833
http://dx.doi.org/10.3325/cmj.2014.55.621
work_keys_str_mv AT milicicdavor antithromboticsinheartfailure
AT samardzicjure antithromboticsinheartfailure
AT petricevicmate antithromboticsinheartfailure